Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
- Nov 21, 2023Sumitomo Pharma America and Actress Holly Robinson Peete Extend Time To Go™ Campaign to Empower People with Overactive Bladder
–Time To Go™ Campaign Encourages People Experiencing Overactive Bladder (OAB) Symptoms to Talk to Their Healthcare Provider about Symptoms, Seek Diagnosis and Ask About GEMTESA® (Vibegron)–...
Nov 3, 2023Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of Hematology Annual Meeting
– ASH Preliminary Data Includes New Clinical Results in Relapsed or Refractory Myelofibrosis (TP-3654) and Relapsed or Refractory Acute Leukemia (DSP-5336) – CAMBRIDGE, Mass., Nov. 3, 2023...
Nov 2, 2023European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis
Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland, GmbH ('SMPS') today announce that the European Commission ('EC') has granted...
Oct 23, 2023Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Men with Advanced Prostate Cancer
– ORGOVYX is the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Approved for Advanced Prostate Cancer in Canada – MISSISSAUGA, Ontario, Oct. 23, 2023...
Oct 19, 2023
Sumitomo Pharma Canada, Inc. and Pfizer Canada today announced that Health Canada has granted a Notice of Compliance (NOC) for MYFEMBREE (Relugolix, estradiol and norethindrone acetate tablets)...